{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:31:35Z","timestamp":1789673495299,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11523-018-0560-7","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T19:37:07Z","timestamp":1520537827000},"page":"257-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Targeting BCL-2 in Hematologic Malignancies"],"prefix":"10.1007","volume":"13","author":[{"given":"Nadia","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.3874430","volume":"228","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440\u20133.","journal-title":"Science"},{"key":"560_CR2","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/onc.2015.287","volume":"35","author":"D Merino","year":"2016","unstructured":"Merino D, Lok SW, Visvader JE, et al. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene. 2016;35:1877\u201387.","journal-title":"Oncogene"},{"key":"560_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"MV Gaizo Del","year":"2007","unstructured":"Del Gaizo MV, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117:112\u201321.","journal-title":"J Clin Invest"},{"key":"560_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677\u201381.","journal-title":"Nature"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1158\/1535-7163.MCT-08-1118","volume":"8","author":"P Hauck","year":"2009","unstructured":"Hauck P, Chao BH, Litz J, et al. Alterations in the Noxa\/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther. 2009;8:883\u201392.","journal-title":"Mol Cancer Ther"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00280-014-2530-9","volume":"74","author":"A Kaefer","year":"2014","unstructured":"Kaefer A, Yang J, Noertersheuser P, et al. Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol. 2014;74:593\u2013602.","journal-title":"Cancer Chemother Pharmacol"},{"key":"560_CR7","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163\u20139.","journal-title":"Clin Cancer Res"},{"key":"560_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/CE.S42568","volume":"8","author":"CA Goard","year":"2013","unstructured":"Goard CA, Schimmer AD. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid. 2013;8:15\u201326.","journal-title":"Core Evid"},{"key":"560_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.6004\/jnccn.2017.0030","volume":"15","author":"WG Wierda","year":"2017","unstructured":"Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia\/Small Lymphocytic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017;15:293\u2013311.","journal-title":"J Natl Compr Canc Netw"},{"key":"560_CR10","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","volume":"82","author":"M Hanada","year":"1993","unstructured":"Hanada M, Delia D. Aiello A, et al: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820\u20138.","journal-title":"Blood"},{"key":"560_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"560_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768\u201378.","journal-title":"Lancet Oncol"},{"key":"560_CR13","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278\u201381.","journal-title":"Blood"},{"key":"560_CR14","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","volume":"27","author":"S Stilgenbauer","year":"2009","unstructured":"Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994\u20134001.","journal-title":"J Clin Oncol"},{"key":"560_CR15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.V128.22.637.637","volume":"128","author":"J Jones","year":"2016","unstructured":"Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Blood. 2016;128:637.","journal-title":"Blood"},{"key":"560_CR16","doi-asserted-by":"crossref","unstructured":"Kovacs G, Robrecht S, Fink AM, et al. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J Clin Oncol. 2016;34(31):3758\u201365.","DOI":"10.1200\/JCO.2016.67.1305"},{"key":"560_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230\u201340.","journal-title":"Lancet Oncol"},{"key":"560_CR18","doi-asserted-by":"publisher","first-page":"LBA-2","DOI":"10.1182\/blood-2017-05-781278","volume":"130","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF, et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed\/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood. 2017;130:LBA-2.","journal-title":"Blood"},{"key":"560_CR19","first-page":"428","volume":"130","author":"P Hillmen","year":"2017","unstructured":"Hillmen P, Munir T, Rawstron A, et al. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Blood. 2017;130:428.","journal-title":"Blood"},{"key":"560_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1182\/blood-2017-03-771576","volume":"130","author":"N Jain","year":"2017","unstructured":"Jain N, Thompson PA, Ferrajoli A, et al. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed\/Refractory CLL: A Phase II Trial. Blood. 2017;130:429.","journal-title":"Blood"},{"key":"560_CR21","unstructured":"Park S, Davis L, Hsu P, et al. Phase II\/1b Trial of Ibrutinib Plus Prednisone and Rituximab Induction Followed By Venetoclax Plus Ibrutinib Maintenance in Newly Diagnosed High-Risk Chronic Lymphocytic Leukemia. Blood. 2017;130:5351."},{"key":"560_CR22","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Morschhauser F, Wendtner C-M, et al. Phase Ib Study (GO28440) of Venetoclax with Bendamustine\/Rituximab or Bendamustine\/Obinutuzumab in Patients with Relapsed\/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood. 2016;128:4393.","DOI":"10.1182\/blood.V128.22.4393.4393"},{"key":"560_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2015-05-643387","volume":"126","author":"GA Salles","year":"2015","unstructured":"Salles GA, Boyd TE, Morschhauser F, et al. Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine\/Rituximab in Patients with Relapsed\/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood. 2015;126:4.","journal-title":"Blood"},{"key":"560_CR24","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","volume":"129","author":"K Fischer","year":"2017","unstructured":"Fischer K, Al-Sawaf O, Fink AM, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129:2702\u20135.","journal-title":"Blood"},{"key":"560_CR25","first-page":"430","volume":"130","author":"IW Flinn","year":"2017","unstructured":"Flinn IW, Gribben JG, Dyer MJS, et al. Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). Blood. 2017;130:430.","journal-title":"Blood"},{"key":"560_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","volume":"126","author":"IW Flinn","year":"2015","unstructured":"Flinn IW, Brunvand M, Choi MY, et al. Safety and Efficacy of a Combination of Venetoclax (GDC-0199\/ABT-199) and Obinutuzumab in Patients with Relapsed\/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). Blood. 2015;126:494.","journal-title":"Blood"},{"key":"560_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.V130.Suppl_1.830.830","volume":"130","author":"KA Rogers","year":"2017","unstructured":"Rogers KA, Huang Y, Stark A, et al. Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b\/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. Blood. 2017;130:431.","journal-title":"Blood"},{"key":"560_CR28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V128.22.639.639","volume":"128","author":"JA Jones","year":"2016","unstructured":"Jones JA, Woyach J, Awan FT, et al. Phase 1b Results of a Phase 1b\/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 2016;128:639.","journal-title":"Blood"},{"key":"560_CR29","doi-asserted-by":"crossref","unstructured":"Deng J, Isik E, Fernandes SM, et al. Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL. Blood. 2015;126:490.","DOI":"10.1182\/blood.V126.23.490.490"},{"key":"560_CR30","doi-asserted-by":"crossref","unstructured":"Jayappa KD, Portell CA, Gordon V, et al. Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-1 99). Blood. 2015;126:448.","DOI":"10.1182\/blood.V126.23.448.448"},{"key":"560_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, et al. Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35:826\u201333.","journal-title":"J Clin Oncol"},{"key":"560_CR32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V128.22.617.617","volume":"128","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Topp MS, Yuen SL, et al. Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed\/Refractory Follicular Lymphoma: Interim Data. Blood. 2016;128:617.","journal-title":"Blood"},{"key":"560_CR33","doi-asserted-by":"crossref","unstructured":"Zelenetz AD, Salles GA, Mason KD, et al. Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma. Blood. 2016;128:\u20133032.","DOI":"10.1182\/blood.V128.22.3032.3032"},{"key":"560_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88\u201394.","journal-title":"J Clin Oncol"},{"key":"560_CR35","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"560_CR36","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"560_CR37","doi-asserted-by":"crossref","unstructured":"Tam CSL, Roberts AW, Anderson MA, et al. Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study. J Clin Oncol. 2017;35:7520.","DOI":"10.1200\/JCO.2017.35.15_suppl.7520"},{"key":"560_CR38","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","volume":"94","author":"BC Medeiros","year":"2015","unstructured":"Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94:1127\u201338.","journal-title":"Ann Hematol"},{"key":"560_CR39","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discovery. 2016;6:1106\u201317.","journal-title":"Cancer Discovery"},{"key":"560_CR40","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401\u20137.","DOI":"10.1002\/ajh.25000"},{"key":"560_CR41","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"560_CR42","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016;15:1132\u201344.","journal-title":"Mol Cancer Ther"},{"key":"560_CR43","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401\u20139.","journal-title":"Blood"},{"key":"560_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.leukres.2015.12.005","volume":"41","author":"SK Edwards","year":"2016","unstructured":"Edwards SK, Han Y, Liu Y, et al. Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells. Leuk Res. 2016;41:85\u201395.","journal-title":"Leuk Res"},{"key":"560_CR45","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood. 2017;130:2392\u2013400.","journal-title":"Blood"},{"key":"560_CR46","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977\u201389.","journal-title":"Cell"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0560-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T17:48:47Z","timestamp":1660585727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0560-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0560-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]},"assertion":[{"value":"8 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and Ethical Standards"}},{"value":"Dr. Kahl has consulted for Abbvie and Pharamcyclics. Dr. Khan has consulted for Gilead and Abbvie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}